HPLC with ICP-MS or ESI-MS detection has been used to investigate metal-containing reaction intermediates in the ligand exchange process leading to formation of the well known Rh 2 (MEPY) 4 catalyst. A variety of intermediates are observed along the pathway to formation of the desired tetrasubstituted product, including isomeric species from di-, tri-, or tetrasubstitution that were previously believed to be absent.Keywords: catalyst; ESI-MS; HPLC; ICP-MS; metal speciation; rhodium Metals play an increasingly important role in the synthesis of pharmaceuticals.[1] Consequently, detailed studies of metal-containing catalysts and/or intermediates, by-products and impurities are becoming increasingly important.[2] In addition to the conventional tools for organic analysis, metal-containing species can be characterized using ICP-MS, [3] ICP-AES, [4] X-ray fluorescence, [5] electrochemistry, [6] and atomic absorption spectroscopy.[7] Of these techniques, ICP-MS is perhaps most powerful, allowing highly sensitive quantitation of a wide variety of different metals.[8] A drawback of the technique, as typically applied, is that all metals of a certain type, e.g., Pd, are counted together, irrespective of oxidation state or the presence/absence of coordinating ligands. However, when coupled with HPLC or other separation techniques, ICP-MS can provide information on the metal content of chromatographically resolved species, [9] suggesting a possible role in the study of metal-containing species in organic reactions, catalyst degradation, or recalcitrant metal impurity problems.While widely studied in environmental analysis, [10] metal speciation tools are seldom used in pharmaceutical process research. We therefore undertook an investigation into the utility of HPLC-ICP-MS, as well as more conventional HPLC-ESI-MS, in the study of a model ligand exchange reaction: the formation of dirhodium(II) tetrakis[methyl-2-oxopyrrolidin-5(S)-carboxylate], Rh 2 (MEPY) 4 , from rhodium acetate and methyl pyroglutamate. The Rh 2 (MEPY) 4 catalyst is one of a series of enantioselective catalysts developed by Doyle and co-workers [11] and is based on amide ligand substitution around a dirhodium core.[12] These catalysts have proven useful in a number of enantioselective transformations, especially enantioselective cyclopropanation and CH insertion processes involving the formation of transient metal-carbene intermediates.[13] The structure of the reported catalyst (Scheme 1), based on X-ray crystallographic evidence, [11] has two oxygens and two nitrogens bound to each rhodium, with the two nitrogens (or two oxygens) oriented cis to one another: the (cis-2,2) configuration.The formation of dirhodium(II) carboxamidate compounds from rhodium acetate has been well studied [12 -14] and is believed with the Rh 2 (MEPY) 4 catalyst to involve the successive displacement of acetate ligands from the rhodium acetate precursor by methyl pyroglutamate (MEPY). Catalyst formation is complicated by